Vaderis Therapeutics closed an oversubscribed $152 million Series B to advance engasertib (VAD-044) toward a Phase 3 program for hereditary hemorrhagic telangiectasia (HHT). The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors. The company is using the financing to propel the next clinical milestone in HHT, a rare bleeding disorder where there remains unmet need for disease-modifying options. The deal also signals investor appetite for targeted development programs in rare disease vascular pathways. Beyond the cash infusion, the size of the raise suggests confidence that engasertib can clear the translation gap from earlier data into a pivotal study designed to support market access.